Your browser doesn't support javascript.
loading
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents.
Dürr, Pauline; Schlichtig, Katja; Kelz, Carolin; Deutsch, Birgit; Maas, Renke; Eckart, Michael J; Wilke, Jochen; Wagner, Harald; Wolff, Kerstin; Preuß, Caroline; Brückl, Valeska; Meidenbauer, Norbert; Staerk, Christian; Mayr, Andreas; Fietkau, Rainer; Goebell, Peter J; Kunath, Frank; Beckmann, Matthias W; Mackensen, Andreas; Neurath, Markus F; Pavel, Marianne; Dörje, Frank; Fromm, Martin F.
Afiliação
  • Dürr P; Pharmacy Department, Erlangen University Hospital, Erlangen, Germany.
  • Schlichtig K; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Kelz C; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Deutsch B; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Maas R; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Eckart MJ; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Wilke J; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Wagner H; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Wolff K; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Preuß C; Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Brückl V; Practice for Hematology and Oncology, Erlangen, Germany.
  • Meidenbauer N; Practice for Hematology and Oncology, Fürth, Germany.
  • Staerk C; Practice for Hematology and Oncology, Fürth, Germany.
  • Mayr A; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Fietkau R; Department of Internal Medicine 1, University Hospital Erlangen, Erlangen, Germany.
  • Goebell PJ; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Kunath F; Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany.
  • Beckmann MW; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Mackensen A; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
  • Neurath MF; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Erlangen, Germany.
  • Pavel M; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
  • Dörje F; Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
  • Fromm MF; Institute of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
J Clin Oncol ; 39(18): 1983-1994, 2021 06 20.
Article em En | MEDLINE | ID: mdl-33822650

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Drogas em Investigação / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Drogas em Investigação / Neoplasias / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article